Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT03514329
NA

Vapor Ablation for Localized Cancer Lesions

Sponsor: Uptake Medical Technology, Inc.

View on ClinicalTrials.gov

Summary

This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of the inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment. Patients will be followed for up to 12 months.

Official title: Vapor Ablation for Localized Cancer Lesions of the Lung - A Clinical Feasibility Definitive Treatment Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-09-01

Completion Date

2028-06-30

Last Updated

2025-02-27

Healthy Volunteers

No

Interventions

DEVICE

Bronchoscopic Thermal Vapor Ablation

Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.

Locations (2)

Otto-Wagner Hospital

Vienna, Austria

Azienda Ospedaliero - Universitaria

Ancona, Italy